Literature DB >> 22914049

Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors.

Suzanne van Duikeren1, Marieke F Fransen, Anke Redeker, Brigitte Wieles, Gerard Platenburg, Willem-Jan Krebber, Ferry Ossendorp, Cornelis J M Melief, Ramon Arens.   

Abstract

CD8(+) T cells have the potential to attack and eradicate cancer cells. The efficacy of therapeutic vaccines against cancer, however, lacks defined immune correlates of tumor eradication after (therapeutic) vaccination based on features of Ag-specific T cell responses. In this study, we examined CD8(+) T cell responses elicited by various peptide and TLR agonist-based vaccine formulations in nontumor settings and show that the formation of CD62L(-)KLRG1(+) effector-memory CD8(+) T cells producing the effector cytokines IFN-γ and TNF predicts the degree of therapeutic efficacy of these vaccines against established s.c. tumors. Thus, characteristics of vaccine-induced CD8(+) T cell responses instill a predictive determinant for the efficacy of vaccines during tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22914049     DOI: 10.4049/jimmunol.1201540

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8+ T cells.

Authors:  Tihana Tršan; Kristina Vuković; Petra Filipović; Ana Lesac Brizić; Niels A W Lemmermann; Kilian Schober; Dirk H Busch; William J Britt; Martin Messerle; Astrid Krmpotić; Stipan Jonjić
Journal:  Eur J Immunol       Date:  2017-07-04       Impact factor: 5.532

2.  Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes.

Authors:  Jonathan Filskov; Marianne Mikkelsen; Paul R Hansen; Jan P Christensen; Allan R Thomsen; Peter Andersen; Jens Bukh; Else Marie Agger
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

3.  Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.

Authors:  Yinin Hu; Mark E Smolkin; Emily J White; Gina R Petroni; Patrice Y Neese; Craig L Slingluff
Journal:  Ann Surg Oncol       Date:  2014-05-20       Impact factor: 5.344

4.  Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity.

Authors:  Daniel O Villarreal; Megan C Wise; Jewell N Walters; Emma L Reuschel; Min Joung Choi; Nyamekye Obeng-Adjei; Jian Yan; Matthew P Morrow; David B Weiner
Journal:  Cancer Res       Date:  2014-01-21       Impact factor: 12.701

5.  A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model.

Authors:  Hu Liu; Shuang Geng; Congcong Feng; Xiaoping Xie; Bing Wu; Xuan Chen; Qiang Zou; Shuang Wang; Jiantao Cui; Rui Xing; Wenmei Li; Youyong Lu; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

Review 6.  Informatics for cancer immunotherapy.

Authors:  J Hammerbacher; A Snyder
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

7.  Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Authors:  Lionel Apetoh; Mark J Smyth; Charles G Drake; Jean-Pierre Abastado; Ron N Apte; Maha Ayyoub; Jean-Yves Blay; Marc Bonneville; Lisa H Butterfield; Anne Caignard; Chiara Castelli; Federica Cavallo; Esteban Celis; Lieping Chen; Mario P Colombo; Begoña Comin-Anduix; Georges Coukos; Madhav V Dhodapkar; Glenn Dranoff; Ian H Frazer; Wolf-Hervé Fridman; Dmitry I Gabrilovich; Eli Gilboa; Sacha Gnjatic; Dirk Jäger; Pawel Kalinski; Howard L Kaufman; Rolf Kiessling; John Kirkwood; Alexander Knuth; Roland Liblau; Michael T Lotze; Enrico Lugli; Francesco Marincola; Ignacio Melero; Cornelis J Melief; Thorsten R Mempel; Elizabeth A Mittendorf; Kunle Odun; Willem W Overwijk; Anna Karolina Palucka; Giorgio Parmiani; Antoni Ribas; Pedro Romero; Robert D Schreiber; Gerold Schuler; Pramod K Srivastava; Eric Tartour; Danila Valmori; Sjoerd H van der Burg; Pierre van der Bruggen; Benoît J van den Eynde; Ena Wang; Weiping Zou; Theresa L Whiteside; Daniel E Speiser; Drew M Pardoll; Nicholas P Restifo; Ana C Anderson
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

8.  Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.

Authors:  Eleni Maria Varypataki; Koen van der Maaden; Joke Bouwstra; Ferry Ossendorp; Wim Jiskoot
Journal:  AAPS J       Date:  2014-11-12       Impact factor: 4.009

9.  Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models.

Authors:  Mareike Grees; Adi Sharbi-Yunger; Christos Evangelou; Daniel Baumann; Gal Cafri; Esther Tzehoval; Stefan B Eichmüller; Rienk Offringa; Jochen Utikal; Lea Eisenbach; Viktor Umansky
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

Review 10.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.